Pfizer Tablet Lowers The Risk Of Hospitalization From COVID

Pfizer Tablet Lowers The Risk Of Hospitalization From COVID

Pfizer announced on Friday that an experimental coronavirus-fighting tablet lowered the risk of hospitalization and death in high-risk patients who took part in a trial of the medicine.

The business intends to someday sell the tablet to individuals to take at home before they get sick enough to go to the hospital, in conjunction with an earlier antiviral medicine called ritonavir.

Pfizer Tablet Lowers The Risk Of Hospitalization From COVID

Covid-19 showed an 89 percent reduction in the risk of hospitalization or death if patients received it quickly enough, according to an interim analysis done before the trial was set to conclude.

Pfizer Tablet Lowers The Risk Of Hospitalization From COVID

The results were so compelling that the firm halted the experiment and is now prepared to petition the US Food and Medicine Administration for emergency approval of the drug.

In a statement, Pfizer CEO Albert Bourla remarked, “Today’s announcement represents a genuine game-changer in the worldwide efforts to end the destruction of this epidemic.”

Pfizer announced the findings in a press release and did not invite scientists to examine the findings before they were made public. There has been no peer review or publication of the data. More details will be revealed in a peer-reviewed publication and in a filing to the FDA, according to the business.

Bourla said the corporation expected to submit data to authorities as quickly as possible, maybe before Thanksgiving, on CNN New Day on Friday.

The medicine has been tested in persons with Covid-19 who are thought to be at high risk of developing severe disease. Within three or five days following the onset of their symptoms, the participants were randomly assigned to receive either the pill combination or a placebo.

The pill, Paxlovid, is a protease inhibitor, and it’s also known by the experimental designation PF-07321332. Its goal is to keep the virus from spreading further. It decreases the breakdown of ritonavir in the body, according to the company.

Pfizer reported that three out of 389 patients who received the medicine combination within three days were hospitalized within four weeks, compared to 7% of patients who received placebos, or 27 out of 385. According to Pfizer, seven of those who received placebos died. No one who received the therapy died within a month of receiving it.

The results were “a tremendous day for mankind,” according to Bourla, who added that they occurred over a year after the business announced preliminary results for its Covid-19 vaccine, which was issued on November 9, 2020.

Despite the fact that the medication has the potential to save millions of lives, Bourla wants to underline the necessity of immunization. Vaccines, on the other hand, are not 100 percent effective, and

Remdesivir, marketed as Veklury, is the only antiviral currently licensed by the FDA for the treatment of Covid-19. It’s administered by intravenous infusion, therefore it’s not as straightforward to use as a tablet.

Monoclonal antibodies, which are injected or infused medicines that jumpstart the immune system to help fight infection, can also be used to treat people. They are more difficult to take than pills and must be given by a skilled specialist.

Merck is requesting emergency use permission from the FDA for molnupiravir, a home-use antiviral pill. It has been demonstrated to minimize the likelihood of hospitalization or mortality by roughly half. 


Please enter your comment!
Please enter your name here